

**Malin Corporation plc**

**("Malin" or "the Company")**

**Malin investee company Novan announces positive Phase 2 trial data for its antiviral candidate SB206 for the treatment of molluscum contagiosum**

**Dublin-Ireland, 15 November 2018:** Malin Corporation plc's (ISE:MLC) investee company, Novan Inc. ("Novan") (NASDAQ:NOVN), announced positive preliminary top line results for three full cohorts of four from a Phase 2 clinical trial for its topical antiviral candidate SB206 for the treatment of molluscum contagiosum, a contagious skin infection caused by the molluscipox virus.

The SB206 gel demonstrated a clear treatment effect on the complete clearance of all molluscum lesions at Week 12 under both 8% and 12% twice-daily dosages. The safety and tolerability profiles were favourable overall, with no serious adverse events reported. Results for Cohort 4, a 12% once-daily dosage, are targeted to be announced in December. Novan plans to request an end-of-Phase 2 meeting with the US Food and Drug Administration (FDA) before year-end.

Malin owns approximately 10% of Novan and carried its investment in Novan at €5.3 million at 30 June 2018.

A copy of the Novan press release announcing the Phase 2 trial data can be found [here](#).

**ENDS**

**For further information, please contact:**

**Malin**

Jessica Bergin, Director of Investor Relations and External Reporting

Tel: +353 (0)1 901 5700

[investorrelations@malinplc.com](mailto:investorrelations@malinplc.com)

**Powerscourt (Ireland PR)**

Eavan Gannon

Tel: +353 87 236 5973

[malin@powerscourt-group.com](mailto:malin@powerscourt-group.com)

**Consilium Strategic Communications (UK PR)**

Mary-Jane Elliott / Jonathan Birt

Tel: +44 (0)20 3709 5700

[malin@consilium-comms.com](mailto:malin@consilium-comms.com)





## **Davy Corporate Finance (ESM Adviser)**

Brian Garrahy / Daragh O'Reilly

Tel: +353 1 679 6363

## **About Malin Corporation plc**

Malin (ISE:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on Euronext Dublin. For more information visit [www.malinplc.com](http://www.malinplc.com)

